Farmako GmbH, a wholly-owned subsidiary of Agraflora Organics International Inc (OTCMKTS:AGFAF), has applied for EU-GMP (EU Good Manufacturing Practice) Certification. It also applied for the manufacturing and import authorization (MIA), which is permitted under the German Medical Products Act. It expects that this summer will complete processes for EU-GMP and MIA.
Commences cannabis medical products import
Farmako can commence the import of medical cannabis products from outside EEC (European Economic Community) on obtaining MIA and GMP Certification. It allows Farmako to ensure availability of cannabis medical products and scale up distribution in EU and Germany.
Germany established the highest standards in safety
Chief Executive Officer of Farmako, Katrin Eckmans, said Germany has established the highest standards for ensuring the safety of the medical patients in the world. It also helps to improve trust to patients, pharmacists, and physicians. Therefore, it is a challenge for businesses to establish a footprint in the German market place where a limited supply of medical cannabis products prevails. Farmako seeks MIA and EU-GMP certifications to improve the availability of medical cannabis products and provide high-quality products to patients in Germany.
Receives special authorization from BfArm
The German Federal Institute for Drugs and Medical Devices (“BfArM”) has given special authorization to Farmako to distribute medical cannabis flowers in the nation. The company can distribute medical cannabis flowers, which are subjected to ionizing radiation treatment. Therefore, EU-GMP certification, along with MIA, positions Farmako as a leader in the supply of cannabis medical products. The management of Farmako is of the view that additional supply options allow it to scale up its business by introducing a wide range of medical products in large volumes.
Health Canada approves to begin extraction
Health Canada has approved Sustainable Growth Strategic Capital Corp (SGS), a subsidiary of AgraFlora, to commence extraction at Greater Toronto facility. SGS is working with farmers in the Canadian cannabidiol business to maximize CBD extraction by optimizing the harvest. It has conducted a trial of hemp biomass extraction in March 2020. The company will use third-party services for hemp biomass extraction. It will sell isolate, distillate, and CBD crude oil.